A3P

Log in
white bpf GMP and GDP of biological products and advanced therapy medicinal products

 

BPF01      
PUBLIC
- Pharmaceutical industry and associated industries producing organic products
- Biotechnology: production, quality control, quality assurance, technical departments, logistics and regulatory affairs
OBJECTIFS
• Understand the new regulatory requirements for organic products in GMP and BPD for the EU and the WHO.
• Review and understand the latest regulations and the recent proposals of Good Manufacturing Practices for Innovative Therapy Drugs (MTI) or Advanced Therapy Medicinal Products (ATMP).
• Develop and validate the conditions of storage and distribution for biological products sensitive to temperature.

MOYENS PEDAGOGIQUES
En début de session, grâce à un questionnaire, le formateur analyse le niveau de connaissances des professionnels sur le sujet ainsi que leurs attentes des connaissances à acquérir.
Le formateur adapte le programme de la formation en fonction du profil des différents participants. Un temps est consacré aux échanges d’expériences entre participants et avec le formateur.
Pour un bon suivi du stage, le stagiaire dispose d’un ou plusieurs supports de cours en version numérique et en version papier.

 

PROGRAM NOTE MOYENNE
15 5given by previous interns

DUREE
1 day


PROCHAINE SESSION
session Cancelled

FORMATEUR
Laurent LAGANIER
trainer consultant 


TARIF
800 € HT
(Déjeuner inclus)


PICTO telechargerPDF 01


inscriptionbpf
This training is based on the presentation, understanding and applying the latest GMP requirements and BPD applicable to biological and biotechnological products. It includes a review of Annex 2 2014 and 2014 BPDG and those of WHO for BPD and temperature sensitive products. The specifics of therapy products are reviewed and discussed in relation to their specific GMP regulations.
EU Annex 2 2012
• Background: EU law, why a new Annex 2, scope
• Presentation: common part, specific part to the different categories of organic productsand biotechnology
• Conclusion: key developments and possible future changes

Innovative therapy drugs
• Background: binding regulation and its likely developments in GMP / GMP
• Presentation: the different types of MTI and MTI Prepared Selectively (MTI-PP), hospital exemption, changes and challenges

Good Distribution Practices
• Regulatory requirements 2013 EU GDP and GDP WHO TRS Annex 957 5 2010 and TRS, 961 Annex 6 2011 TTSPP
• Main and new requirements of EU GDP / BPDG
• Specifics of the WHO requirements for biological products thermosensitive

Évaluation des connaissances acquises et évaluation des actions d’améliorations entreprises et/ou envisagées

Questionnaire de satisfaction

   
Cette journée s’inscrit dans le cadre de la formation professionnelle.
N° Déclaration : 82 69 13448 69 Préf. Région Rhône-Alpes
SARL au capital de 10 000 Euros Siret 451 934 541 00025

logo a3p training vf

Knowledge enhancement and its mastery

Throughout the year, A3P brings together
experts to offer you professionals quality
training sessions.

couv2017 200 shadow

2017 training program

 

letterA3P Training newsletter

 
E-mail.

Tel.
Fax.

a3pformation@a3pservices.com
+33 (0)4 37 28 30 49
+33 (0)4 37 28 30 60

Hotels near A3P Training Site

local

A unique training space in the heart of Lyon

All our courses are held in modern and welcoming space at 30 rue Pre Gaudry Lyon 7ème.

pause

If you want to rent our space, you will find below all the necessary information.

More information on renting